European biotechs have been longly undervalued. In the wake of the COVID-19 pandemic, some of them took off. They will have to prove their value in a post-COVID era. However, Europe is there.

The B.1.1.7 variant of SARS-CoV-2, which was first identified in the UK, may be associated with an increased risk of death, a Nature study suggests.

Roche to acquire GenMark Diagnostics, Inc., to access platform to test for broad range of pathogens with one patient sample.

While media reports suggest AstraZeneca’s COVID-19 jab might have caused blot clots, the EMA didn’t confirm a causal relationship.

Swiss Roche AG has missed the primary endpoint in the REMDACTA trial in patients with severe COVID-19 pneumonia. 

Africa produces less than 1% of the human vaccines it uses. To effectively respond in time of outbreaks and pandemics, Africa must expand its vaccine development and production capabilities to cater for its growing population. Successfully establishing such an industry at scale is a multifaceted endeavour to create an enabling environment. This article highlights key factors and considerations for establishing local vaccine manufacturing.

The current debates regarding vaccine production and logistics have also made it clear even to the layman: Pharmaceutical production depends on cold. Temperatures below -80?°C are just as common as the requirement to freeze precursors such as blood plasma within a specified time period. Refrigeration specialists with pharmaceutical know-how are in demand for these challenging tasks.

Torben Osterlund is the new Chief Scientific Officer of the Dutch biotech company Toxys B.V., based in Leiden

Danish sustainable crop protection company, BioPhero AS, has raised $17m in Series A funding led by DCVC Bio.

German researchers have presented a new method to assess on-target and off-target effects of CRISPR-Cas nucleases or TALENs.